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Abstract
Background: Prognostic markers specific to a particular cancer type can assist in the evaluation of survival
probability of patients and help clinicians to assess the available treatment modalities.
Methods: Gene expression data was analyzed from three independent colon cancer microarray gene expression
data sets (N = 1052). Survival analysis was performed for the three data sets, stratified by the expression level of the
LINE-1 type transposase domain containing 1 (L1TD1). Correlation analysis was performed to investigate the role of
the interactome of L1TD1 in colon cancer patients.
Results: We found L1TD1 as a novel positive prognostic marker for colon cancer. Increased expression of L1TD1
associated with longer disease-free survival in all the three data sets. Our results were in contrast to a previous study on
medulloblastoma, where high expression of L1TD1 was linked with poor prognosis. Notably, in medulloblastoma L1TD1
was co-expressed with its interaction partners, whereas our analysis revealed lack of co-expression of L1TD1 with its
interaction partners in colon cancer.
Conclusions: Our results identify increased expression of L1TD1 as a prognostic marker predicting longer disease-free
survival in colon cancer patients.
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Background
Colon cancer is the third leading cancer, both in terms
of newly diagnosed cases and mortality [1]. Despite the
fact that chemotherapeutic agents, such as oxaliplatin
and irinotecan, have markedly improved the survival rate
in colon cancer [2], identification of patients likely to re-
spond well to chemotherapy could increase the survival
rate. Our study identifies LINE-1 type transposase do-
main containing 1 (L1TD1) as a novel positive prognos-
tic marker for colon cancer.
Stem cell-like gene signatures have been detected in vari-
ous cancers [3, 4], and embryonic stem cell factors have
been associated with enhanced tumorigenesis and poor
prognosis [5–7]. L1TD1 is an RNA-binding protein required
for self-renewal of undifferentiated embryonic stem cells [8].
Recently, L1TD1 protein was shown to form a core inter-
action network with the canonical pluripotency factors
OCT4, NANOG, LIN28, and SOX2 in human embryonic
stem cells (hESCs) [9], and L1TD1 depletion resulted in
downregulation of the pluripotency markers OCT4,
NANOG, and LIN28 in hESCs [10]. L1TD1 has previously
been shown to be essential for self-renewal of embryonal
carcinoma cells [10] and to support the growth of seminoma
cells [10].
We studied L1TD1 immunoexpression in colon adeno-
carcinoma tissue sections and analyzed three independent
gene expression microarray data sets of colon cancer pa-
tients to assess the prognostic significance of L1TD1 in
colon cancer [11–13]. Our findings suggest that L1TD1 is
a promising prognostic marker for colon cancer.
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Methods
Microarray data sets
Raw microarray data sets (Table 1) were downloaded from
Gene Expression Omnibus (GEO) [17]. Three colon can-
cer gene expression microarray data sets comprising a
total of 1052 clinical samples were analyzed [11–13]. Ei-
ther due to non-tumoral origin (i.e. normal tissue) or due
to missing associated survival information, 124 samples
had to be excluded from the survival analysis (928 samples
remained). Additionally, two seminoma [14, 15] and one
stem cell [16] gene expression microarray data sets were
analyzed to assess the co-expression of L1TD1 and its
interaction partners (Additional file 2: Table S1). The stem
cell data set was composed of samples from ten hESCs, 49
induced pluripotent stem cells (iPSCs), five cancer cell
lines, and six non-cancerous somatic cell lines. A sum-
mary of the data sets used is presented in Table 1.
Gene expression analysis
The CEL files, containing the probe intensity measure-
ments of the Affymetrix probes were normalized using
the Universal exPression Code (UPC) normalization
method from the Bioconductor package “SCAN.UPC”
[18] and the Robust Multiarray Average (RMA)
normalization method from the Bioconductor package
“affy” [19, 20]. The UPC normalization method provides
a score between 0.0 and 1.0, which represents the prob-
ability of a particular gene being expressed in a particu-
lar sample [18]. The UPC scores were used to categorize
the samples in all data sets based on their L1TD1 ex-
pression status as L1TD1 high (UPC > =0.60) and
L1TD1 low (UPC < 0.60). The UPC threshold of 0.6 was
determined by calculating a weighted mean (by sample
size) of the local minima between the two peaks in the
bimodal distributions of UPC scores for L1TD1 over the
three colon cancer data sets (Additional file 1: Fig. S1).
RMA provides normalized log2 intensity values. RMA
normalized gene expression values were used to calcu-
late pairwise correlations between genes. To correct for
multiple testing, the false discovery rate (FDR) was con-
trolled using the Benjamini-Hochberg procedure [21].
The probe “219955_at” was chosen as the primary probe
for the quantification of L1TD1 because it was present
in both of the Affymetrix platforms used in this study
(HG-U133Plus2 and HG-U133A).
Gene list descriptions
Interaction partners
The 311 interaction partners of L1TD1 were determined
using mass spectrometry and co-immunoprecipitation in
our earlier study [9]. 306 interaction partners of L1TD1
were identified by performing a mass spectrometry ana-
lysis on co-immunoprecipitated proteins with two differ-
ent anti-L1TD1 antibodies (recognizing different
epitopes on L1TD1). In addition, for 5 proteins
(NANOG, OCT4 (POU5F1), SOX2, DNMT3B, and
TRIM28) that were challenging to detect using mass
spectrometry, the interactions were shown using immu-
noprecipitation and Western blotting. Out of the 311
interaction partners, 285 corresponded to genes that had
probes associated to them in the microarray platforms
used in this study.
Top 20 interaction partners
The top 20 interaction partners of L1TD1 were deter-
mined on the basis of their co-expression with L1TD1 in
the seminoma and stem cell data sets. First, the inter-
action partners were ranked in descending order of their
Spearman rank correlation value with L1TD1 in these
data sets. Then, the maximum rank over the data sets
was selected as a representative statistic for each inter-
action partner. The list was ordered (ascending) based
on this maximum rank and 20 interaction partners were
selected from the top of the list.
Top 20 co-expressed genes with L1TD1 in colon cancer
Out of all the genes in the microarray data sets (27213
unique probe-gene mappings), top 20 genes were se-
lected based on their co-expression with L1TD1 in the
colon cancer data sets. First, all the genes in the micro-
array data sets were ranked in descending order of their
Spearman rank correlation value with L1TD1 separately
for each colon cancer data set. Then, the maximum rank
over these data sets was selected as a representative
Table 1 Summary of the data sets used in the study. The GEO accession numbers (GEO ID) are listed together with alias names
used to refer to the individual data sets, the microarray platform, the total number of samples, and the number of samples used in
the survival analysis
GEO ID Total Samples Survival Analysis Platform Alias
GSE14333 [11] 290 226 Affymetrix HG-U133Plus2 colon1
GSE17536 [12] 177 145 Affymetrix HG-U133Plus2 colon2
GSE39582 [13] 585 557 Affymetrix HG-U133Plus2 colon3
GSE3218 [14] 107 Not used Affymetrix HG-U133A seminoma1
GSE10783 [15] 34 Not used Affymetrix HG-U133A seminoma2
GSE42445 [16] 70 Not used Agilent-028004 SurePrint G3 Human GE 8x60K hESC1
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statistic for each gene. The list was ordered (ascending)
based on this maximum rank and 20 genes were selected
from the top of the list.
Survival analysis of microarray data
Disease-free survival was analyzed in each data set with
the Kaplan-Meier method as implemented in the R
package “survival” [22, 23] and survival curves were plot-
ted using the R package “survminer” [24]. The log-rank
test was used to compare survival rates between the two
L1TD1 groups (L1TD1 high and L1TD1 low).
Association between L1TD1 expression and
clinicopathological variables
We investigated the association of age and sex and other
publicly accessible clinicopathological variables to the
L1TD1 gene expression in the three gene expression data
sets. The variables included cancer stage [11–13], prior-
therapy received by the patients [11–13], tumor location
[11–13], chromosomal instability [13], CpG island methy-
lation status [13], DNA mismatch repair proficiency [13],
mutation status of BRAF (B-Raf proto-oncogene, serine/
threonine kinase), mutation status of KRAS (KRAS proto-
oncogene, GTPase), and mutation status of TP53 (Tumor
Protein p53) [13]. For variables with only two categories,
Wilcoxon rank sum test [25] was used for the analysis of
statistical significance. For variables with more than two
categories, Kruskal-Wallis test [26] was used. Association
of L1TD1 expression with age was investigated using
Pearson correlation [27].
Analysis of TCGA Colon adenocarcinoma RNA-seq data
set
RNA-seq data from The Cancer Genome Atlas Colon
Adenocarcinoma [28] (TCGA-COAD) data set was
acquired from Genomic Data Commons (portal.gdc.
cancer.gov). The FPKM-UQ normalized (Fragments
Per Kilobase of transcript per Million mapped reads
Upper Quartile) RNA-seq counts from the primary
tumor samples (N = 521) were used to validate the
correlation analyses performed using the microarray
data sets. Due to lack of an evident choice of the in-
tensity threshold to designate samples into high and
low L1TD1 expression groups, we fitted a mixture of
two Gaussian distributions and evaluated two differ-
ent thresholds (Additional file 1: Figure S2): FPKM-
UQ value where the ratio of the two Gaussian distri-
butions was equal, and FPKM-UQ value where the
ratio of the two Gaussian distributions was 10%.
These two thresholds were then used to perform
survival analysis using disease-free survival with
Kaplan-Meier method.
Results
High expression of L1TD1 associates with longer disease-
free survival
Across the three colon cancer microarray data sets,
26.7% of the colon cancer patients were categorized to
have high L1TD1 expression (Table 2, Additional file 1:
Figure S3). The proportion was lower than that observed
in seminoma (48.6 and 50%) and stem cell (88.6%) data
sets (Table 2, Additional file 1: Figure S3).
Kaplan-Meier analysis of 928 samples from the three
colon cancer data sets revealed that the colon cancer
samples with high L1TD1 expression had longer disease-
free survival as compared to those with no/low L1TD1
expression (Fig. 1). The difference was statistically sig-
nificant in all the three data sets (log-rank test P < 0.05).
L1TD1 expression was higher in the samples from
early cancer stages as compared to those from later
stages in all the three data sets (P < 0.05), whereas dif-
ferences between the later stages were typically not sta-
tistically significant (Additional file 1: Figure S4A-C). In
the dataset colon3, L1TD1 expression was high for
samples with mutated KRAS (P < 0.0001), wild-type
TP53 (P < 0.0001), and negative chromosomal instability
marker (P < 0.0001) (Additional file 1: Figure S4D-F).
Additionally, significant associations were observed
between L1TD1 expression and tumor location or
tumor differentiation status (P < 0.0001) (Additional
file 1: Figure S4G-I). Age, sex, prior therapy (chemo-,
radio- or adjuvant therapy), BRAF mutation status,
CpG island methylation status, or DNA mismatch re-
pair proficiency did not show statistically significant
associations with the L1TD1 expression (Additional
file 1: Figure S5).
Interactome of L1TD1 is not co-expressed in colon cancer
To examine the potential role of the previously identi-
fied interaction partners of L1TD1 [9] (Additional file 2:
Table S1) in its prognostic performance in colon cancer,
Spearman rank correlation matrices were calculated
Table 2 Proportion of samples with high expression of L1TD1.
The samples were categorized based on their L1TD1 expression
level (high L1TD1+ or low L1TD1-) in the different data sets used
in this study. For the colon cancer data sets, only tumor
samples with complete survival information were considered
Data set L1TD1 + L1TD1 - Total Percentage of L1TD1 +
colon1 64 162 226 28.3%
colon2 44 101 145 30.3%
colon3 140 417 557 25.1%
Total (Colon Cancer) 248 680 928 26.7%
seminoma1 52 55 107 48.6%
seminoma2 17 17 34 50.0%
hESC1 62 8 70 88.6%
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between the expression levels of L1TD1 and its interaction
partners [9]. Interestingly, the high positive correlation ob-
served among L1TD1 and its top 20 interaction partners
in seminoma and stem cell data sets (P < 0.0001, Fig. 2a)
was absent in all three colon cancer data sets (Fig. 2b).
However, the interaction partners did not consistently im-
prove the predictive prognostic power obtained with
L1TD1 alone (Additional file 2: Table S2).
Genes co-expressed with L1TD1 in colon cancer
We identified genes that were co-expressed with L1TD1
in colon cancer patients using Spearman rank correlation
(Table 3, Additional file 2: Table S3). Although none of
the top 20 co-expressed genes outperformed L1TD1 as in-
dependent prognostic marker for colon cancer in all the
three data sets, five genes had statistically significant (P <
0.05) impact on survival in at least two out of the three
colon cancer data sets (Table 4): Serine peptidase inhibitor
Kazal type 4 (SPINK4), Resistin-like beta (RETNLB),
Asparaginase-like 1 Protein (ASRGL1), Chloride channel
accessory 1 (CLCA1), and Fc fragment of IgG binding pro-
tein (FCGBP) (Additional file 1: Figure S6).
Validation in TCGA Colon adenocarcinoma RNA-seq data
set
To further validate our findings from the three colon
cancer microarray data sets, we analyzed the TCGA
Colon Adenocarcinoma [28] (TCGA-COAD) RNA-seq
data set containing 521 patient samples. When the sam-
ples were stratified for L1TD1 expression using the
threshold where the ratio of the two Gaussian distribu-
tions was 10%, Kaplan-Meier analysis supported that the
colon cancer samples with high L1TD1 expression had
longer disease-free survival as compared to those with
no/low L1TD1 expression (P = 0.038, Additional file 1:
Figure S2C). Additionally, we were able to reproduce the
findings from the correlation analyses, indicating a lack
of correlation between L1TD1 and its top 20 interaction
partners (Additional file 1: Figure S2D) and confirming
significant correlations between L1TD1 and genes that
were co-expressed with L1TD1 in the colon cancer
microarray data sets (Additional file 1: Figure S2E).
Discussion
In this study, we examined the prognostic value of
L1TD1 in colon cancer patients. We found compelling
evidence of L1TD1 being a positive prognostic marker
for colon cancer (Fig. 1). We demonstrated this by sur-
vival analysis of 928 samples from three independent
gene expression data sets of colon cancer patients and
further confirmed the results in the TCGA Colon
Adenocarcinoma RNA-seq data set of 521 colon cancer
patients.
Expression of L1TD1 has earlier been reported to be
highly specific to embryonic stem cells [10], brain [29], and
colon (Additional file 1: Figure S7). Besides these healthy tis-
sues, L1TD1 expression has also been reported in seminoma
[10], embryonic carcinomas [10], medulloblastoma [30], and
colon adenocarcinoma (Additional file 1: Figures S3 and S7).
Expression of L1TD1 at high levels in colon cancer cells led
us to hypothesize that high expression of L1TD1 in colon
cancer might be associated with prognosis. Earlier reports
have demonstrated the association of stem cell pluripotency
factors with poor prognosis in different cancer types,
Fig. 1 Survival curves for colon cancer. Kaplan-Meier curves showing disease-free survival for the three colon cancer data sets (a-c). The curves
present survival data for the two groups of colon cancer patients based on L1TD1 expression level (high or low). The red curve corresponds to
the patients with high L1TD1 expression and the black curve corresponds to the patients with low L1TD1 expression. The x-axis shows disease-
free survival time in years and the y-axis shows the probability of disease-free survival. The risk table shows the number of patients at risk at the
given time point
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Fig. 2 (See legend on next page.)
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including medulloblastoma [30] and seminoma [15]. Inter-
estingly, our results were in contrast with previous studies,
suggesting that in colon cancer, high expression of L1TD1 is
linked to better prognosis. In the three colon cancer data
sets, expression of L1TD1 was associated with samples of
low clinical cancer stage (Additional file 1: Figure S4A-C),
which can perhaps be a reason for its prognostic
significance.
In an attempt to understand the distinctive role of
L1TD1 in different cancers, we investigated the co-ex-
pression of L1TD1 with its currently known interaction
partners. We discovered that, unlike in hESCs and semi-
nomas, L1TD1 was not co-expressed with its interaction
partners in colon cancer (Fig. 2). This points to the po-
tential participation of L1TD1’s interaction partners in
the contrasting prognostic outcome. This was further
supported by a recent study in medulloblastoma,
showing an association of high L1TD1 expression with
poor clinical outcome and significant co-expression
between L1TD1 and its interaction partner OCT4 [30].
Together, these findings suggest that the co-expression
of L1TD1 with its interaction partners might be required
for manifesting an aggressive and detrimental phenotype.
This is the first time that an embryonic stem cell factor
has been shown to lead to contrasting outcomes in can-
cer, taking into consideration to the presence or absence
of strong co-expression with its interaction partners.
We also investigated genes that were co-expressed
with L1TD1 in colon cancer. Among the top 20 co-
expressed genes, six had previously been linked to colon
cancer. Chloride Channel Accessory 1 (CLCA1) is a
tumor suppressor protein that regulates differentiation
and proliferation of colorectal cancer cells. Its low
(See figure on previous page.)
Fig. 2 Co-expression of interaction partners of L1TD1. Heatmaps showing signed P-value of Spearman rank correlation for the 20 most
significantly co-expressed interaction partners of L1TD1 determined on the basis of the seminoma and stem cell data sets. Co-expression in (a)
seminoma and stem cell data sets, and (b) colon cancer data sets. The signed P-value of Spearman rank correlation was defined as 1 - P-value of
Spearman rank correlation multiplied by the sign of the correlation
Table 3 Top 20 co-expressed genes with L1TD1 in colon
cancer. The Spearman rank correlation values (rs) with L1TD1 are
shown together with their false discovery rates (FDR) separately
for each colon cancer data set
colon 1 colon 2 colon 3
Rank Gene Name rs FDR rs FDR rs FDR
1 RETNLB 0.47 9.26E-13 0.53 3.69E-10 0.45 0.00
2 CLCA1 0.45 5.65E-12 0.43 1.10E-05 0.45 0.00
3 HEPACAM2 0.43 1.05E-10 0.41 3.98E-05 0.46 0.00
4 FOXA3 0.41 1.14E-09 0.43 1.06E-05 0.43 0.00
5 FCGBP 0.41 1.14E-09 0.39 2.15E-04 0.47 0.00
6 ST6GALNAC1 0.40 4.55E-09 0.39 1.87E-04 0.43 2.57E-24
7 SPINK4 0.44 2.99E-11 0.38 3.91E-04 0.43 5.06E-25
8 KIAA1324 0.40 4.60E-09 0.44 7.71E-06 0.39 0.00
9 KLF4 0.40 4.60E-09 0.37 4.61E-04 0.41 0.00
10 GMDS 0.46 1.50E-12 0.40 9.95E-05 0.38 0.00
11 SLITRK6 0.43 5.87E-11 0.36 1.14E-03 0.46 0.00
12 SERPINA1 0.42 1.35E-10 0.38 3.84E-04 0.35 1.26E-16
13 LINC00261 0.34 1.45E-06 0.35 2.09E-03 0.48 0.00
14 ITLN1 0.35 4.43E-07 0.33 3.97E-03 0.42 0.00
15 MUC2 0.39 8.64E-09 0.33 4.90E-03 0.38 0.00
16 DEFA5 0.37 5.72E-08 0.35 1.78E-03 0.33 6.77E-14
17 ASRGL1 0.40 4.55E-09 0.32 6.22E-03 0.41 0.00
18 SLC27A2 0.36 2.17E-07 0.36 9.05E-04 0.33 2.44E-13
19 RNF186 0.32 8.44E-06 0.36 1.30E-03 0.34 1.89E-14
20 PCCA 0.37 1.05E-07 0.37 7.52E-04 0.33 2.95E-13
Table 4 Prognostic assessment of genes that co-express with
L1TD1 in colon cancer
Gene colon1 colon2 colon3
L1TD1 0.009729 0.008520 0.018607
SPINK4 0.007148 0.001854 0.880992
RETNLB 0.325642 0.012519 0.009064
ASRGL1 0.015986 0.521116 0.016293
CLCA1 0.030053 0.006496 0.710961
FCGBP 0.028617 0.047080 0.292182
ITLN1 0.088225 0.043802 0.844453
FOXA3 0.077752 0.609721 0.093598
PCCA 0.064797 0.601176 0.107992
DEFA5 0.136904 0.157008 0.737800
GMDS 0.318171 0.170255 0.000919
HEPACAM2 0.368837 0.687066 0.098125
SERPINA1 0.000008 0.493419 0.911649
RNF186 0.700045 0.541107 0.010793
KLF4 0.938136 NA 0.220231
ST6GALNAC1 0.593332 0.880638 0.030027
MUC2 0.624983 0.505661 0.842770
KIAA1324 0.220079 0.969530 0.730810
SLITRK6 0.750696 0.894483 0.085490
LINC00261 0.823520 0.823442 0.269044
SLC27A2 0.883481 0.975288 0.002906
Statistical significance of the top 20 co-expressed genes in the survival analysis
of colon cancer patients in the three data sets. Genes with statistically
significant association with disease-free survival (log-rank test P < 0.05) in at
least two colon cancer data sets are underlined
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expression has been associated with tumorigenesis, metas-
tasis, and chromosomal instability, as well as poor progno-
sis in colorectal cancer [31]. Kruppel Like Factor 4 (KLF4)
is a target of the tumor suppressor gene Adenomatous
Polyposis Coli (APC) and its overexpression reduces cell
migration and invasion in vitro and tumorigenicity of
colon cancer cells in vivo [32]. GDP-mannose-4,6-dehy-
dratase (GMDS) has been shown to have exon deletions
linked to progression of colorectal cancer [33]. Also, an in
vitro study found that GMDS deficiency in colon cancer
cells made them resistant to receptor-mediated apoptosis
[34]. High expression of Mucin 2 (MUC2) has been asso-
ciated with longer disease-free survival in colorectal can-
cer patients [35]. Frameshift mutations resulting in
premature termination of translation of Propionyl-CoA
Carboxylase Alpha Subunit (PCCA) have been reported in
colon and gastric cancer [36]. Investigation of the po-
tential role of Alpha-1-antitrypsin (SERPINA1) expres-
sion in cancers provides controversial results; it has
been associated with good prognosis in breast and
colon cancer on protein atlas [37] (https://www.pro
teinatlas.org/ENSG00000197249-SERPINA1/pathology),
but there are also reports that associate it with poor
prognosis in colon cancer [38], gastric cancer [39]
and cutaneous squamous cell carcinoma [40].
Several of the co-expressed genes have been linked to
various other cancers. Down-regulation of Fc fragment
of IgG binding protein (FCGBP) has been associated
with decreased overall survival in gallbladder adenocar-
cinoma [41] and with progression of prostate cancer in
Transgenic adenocarcinoma Mouse Prostate (TRAMP)
[42]. Upregulation of ST6 N-acetylgalactosaminide
alpha-2,6-sialyltransferase 1 (ST6GALNAC1) has been
associated with good prognosis in breast cancer [43].
Additionally, siRNA-mediated silencing of ST6GALNAC1
has been shown to lead to reduced growth, migration and
invasion of gastric cancer cells in vitro [44]. Estrogen-
Induced Gene 121 Protein (KIAA1324), Long Intergenic
Non-Protein Coding RNA 261 (LINC00261), and
Intelectin 1 (ITLN1) have been shown to function as
tumor suppressors in gastric cancer, with decreased ex-
pression associated with poor prognosis [45–47]. Low
expression of Asparaginase-Like 1 Protein (ASRGL1)
has been suggested as a marker for poor prognosis in
endometrial carcinoma [48], whereas reduced levels of
Solute carrier family 27 member 2 (SLC27A2) have
been associated with poor survival in lung cancer [49].
SLIT and NTRK- like protein 6 (SLITRK6) is a known
bladder tumor antigen, and is currently under investi-
gation in clinical trials as a target for antibody-drug
conjugate therapy [50]. HEPACAM family member 2
(HEPACAM2) is a paralog of Hepatocyte Cell Adhesion
Molecule (HEPACAM), which is known to act as a
tumor suppressor by promoting differentiation [51].
HEPACAM2, however, is a relatively newly-identified
molecule and is not well-studied.
Conclusion
Our study of gene expression data from four clinical
colon cancer data sets produced promising evidence in
support of L1TD1 as a marker for good prognosis in
colon cancer. Our results emphasize the need for further
investigation and validation of L1TD1 as a potential
prognostic marker in larger cohorts of colon cancer.
Finally, this work also underscores the potential merits
of investigating co-expressed genes to markers of
interest.
Additional files
Additional file 1: Figure S1. Density distributions of UPC scores for
L1TD1 in the three colon cancer microarray data sets. A dashed black line
indicates the UPC threshold of 0.6, which was used to stratify the
samples into L1TD1+ and L1TD1- groups in the three data sets. Figure
S2. Analysis of the primary tumor samples in The Cancer Genome Atlas
Colon Adenocarcinoma (TCGA-COAD) data set. (A) Estimation of FPKM-
UQ normalized RNA-seq counts by fitting Gaussian distributions. (B-C)
Kaplan-Meier curves using the two thresholds for designating L1TD1 high
and low samples (grey and red dashed lines, respectively). (D) Heatmaps
showing signed P-value of Spearman rank correlation for the 20 most
significantly co-expressed interaction partners of L1TD1. (E) The
Spearman rank correlation values (rs) between L1TD1 and its top 20 co-
expressed genes (Table 3). The correlations in the TCGA-COAD data set
are shown with their false discovery rate (FDR). Figure S3. Heatmaps
showing expression level of L1TD1 and its top 20 interaction partners in
the samples of (A) colon cancer data sets, and (B) seminoma and stem
cell data sets. Figure S4. Boxplots of UPC scores of L1TD1 stratified
based on the indicated clinicopathological parameters in the different
colon cancer microarray data sets. Figure S5. Boxplots of UPC scores of
L1TD1 stratified based on the indicated clinicopathological parameters in
the different colon cancer microarray data sets. Figure S6. Kaplan-Meier
curves showing disease-free survival for the three colon cancer data sets
(columns). The curves present survival data for the two groups of colon
cancer patients based on gene expression level (high or low) of SPINK4,
RETNLB, ASRGL1, CLCA1, and FCGBP (rows). Grey = high gene expression,
Black = low gene expression. Figure S7. Formalin-fixed and paraffin-
embedded tissue microarray blocks were stained with
immunohistochemistry using anti-L1TD1 (Atlas Antibodies, HPA028501).
(A) Normal colon tissue, (B) colorectal adenocarcinoma sample. (PDF
2132 kb)
Additional file 2: Table S1. 311 Interaction partners of L1TD1 were
determined using Mass spectrometry and co-immunoprecipitation in our
earlier publication (Emani, Närvä, 2015, Stem cell reports). 306 Interaction
partners of L1TD1 were identified by performing a Mass spectrometry
analysis on co-immunoprecipitated proteins with two different anti-
L1TD1 antibodies (recognizing different epitopes on L1TD1). In addition,
we included 5 more proteins (NANOG, OCT4 (POU5F1), SOX2, DNMT3B,
and TRIM28) that were challenging to detect using Mass spectrometry
but the interactions were shown using Immunoprecipitation and Western
Blotting. This makes a total of 311 proteins that are referred to in this
work as “Interaction partners” of L1TD1. Table S2. Colon cancer samples
with a high L1TD1 expression and a concomitant lack of expression of
the listed interaction partner were compared to colon cancer samples
with a low L1TD1 expression in the three data sets, this table lists
the P-values (log-rank test) for these comparisons. P-value less (more
significant) than the one obtained by comparing L1TD1 high and
low sample groups are highlighted. Table S3. Table lists the 20
genes that had a positive correlation with L1TD1 in the colon cancer
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data sets. The table lists their UNIPROT ID and UNIRPOT protein
name. (PDF 211 kb)
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